Compare Danaher Corporation (DHR) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Entegris Inc — how do they compare? Danaher Corporation trades at $201.9 (market cap $140.88B), while Entegris Inc trades at $138.8 (market cap $21.42B). The key difference: Danaher Corporation is far larger — about 6.6× Entegris Inc's market cap, and Danaher Corporation pays the higher dividend (0.8%). Which is the better fit depends on your goals.
| DHR | ENTG | |
|---|---|---|
Market Cap | $140.88B | $21.42B |
Sector | Health | Technology |
52-Week High | $242.05 | $184.00 |
52-Week Low | $161.91 | $68.80 |
Enterprise Value | $153.66B | $24.73B |
Dividend Yield | 0.8% | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
ENTG trades at $136.27, down 6.25% over 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a high P/E of 78.77 but strong recent earnings beats. Revenue remains stable at $3.2B with improving net margins. Analyst consensus is bullish with a $178.40 price target, representing 31% upside potential. Recent developments include a new CFO appointment and strategic licensing agreements in semiconductor technology.
ENTG presents a compelling growth story in semiconductor materials with AI-driven demand catalysts, though premium valuation and technical weakness create near-term headwinds. The company's positioning in advanced chip manufacturing and consistent earnings performance support long-term upside, while current price levels offer entry opportunity below analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
